NOVELLUS Trademark

Trademark Overview


On Friday, July 6, 2018, a trademark application was filed for NOVELLUS with the United States Patent and Trademark Office. The USPTO has given the NOVELLUS trademark a serial number of 88028436. The federal status of this trademark filing is REGISTERED as of Tuesday, March 10, 2020. This trademark is owned by Factor Bioscience LLC. The NOVELLUS trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Products & Electrical & Scientific Products, and Computer & Software Services & Scientific Services categories with the following description:

Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering

Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nu...

Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments

Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
novellus

General Information


Serial Number88028436
Word MarkNOVELLUS
Filing DateFriday, July 6, 2018
Status700 - REGISTERED
Status DateTuesday, March 10, 2020
Registration Number6008685
Registration DateTuesday, March 10, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 18, 2019

Trademark Statements


Goods and ServicesBiochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
Goods and ServicesPharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
Goods and ServicesGene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
Goods and ServicesPharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
Translation of Words in MarkThe wording "NOVELLUS" has no meaning in a foreign language.

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateTuesday, February 19, 2019
Primary Code001
First Use Anywhere DateTuesday, October 1, 2019
First Use In Commerce DateTuesday, October 1, 2019

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 4, 2020
Primary Code005
First Use Anywhere DateMonday, March 31, 2014
First Use In Commerce DateMonday, March 31, 2014

International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateTuesday, February 19, 2019
Primary Code009
First Use Anywhere DateFriday, November 8, 2019
First Use In Commerce DateFriday, November 8, 2019

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 4, 2020
Primary Code042
First Use Anywhere DateMonday, March 31, 2014
First Use In Commerce DateMonday, March 31, 2014

Trademark Owner History


Party NameFactor Bioscience LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02141

Party NameFactor Bioscience LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02141

Party NameFactor Bioscience LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02141

Trademark Events


Event DateEvent Description
Tuesday, March 10, 2020REGISTERED-PRINCIPAL REGISTER
Friday, February 7, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, February 6, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sunday, December 29, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, December 18, 2019USE AMENDMENT FILED
Sunday, December 29, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 18, 2019TEAS STATEMENT OF USE RECEIVED
Tuesday, August 13, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 18, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 18, 2019PUBLISHED FOR OPPOSITION
Wednesday, May 29, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, May 10, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 10, 2019EXAMINER'S AMENDMENT ENTERED
Friday, May 10, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 10, 2019EXAMINERS AMENDMENT E-MAILED
Friday, May 10, 2019EXAMINERS AMENDMENT -WRITTEN
Thursday, May 9, 2019EXAMINER'S AMENDMENT ENTERED
Thursday, May 9, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, May 9, 2019EXAMINERS AMENDMENT E-MAILED
Thursday, May 9, 2019EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 10, 2019NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, April 10, 2019FINAL REFUSAL E-MAILED
Wednesday, April 10, 2019FINAL REFUSAL WRITTEN
Tuesday, February 19, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 19, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 18, 2019ASSIGNED TO LIE
Tuesday, February 12, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, October 27, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, October 27, 2018NON-FINAL ACTION E-MAILED
Saturday, October 27, 2018NON-FINAL ACTION WRITTEN
Thursday, October 25, 2018ASSIGNED TO EXAMINER
Thursday, July 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 10, 2018NEW APPLICATION ENTERED IN TRAM